01.06.2017 | Case report
Apatinib/dabigatran etexilate/erlotinib
Development of erlotinib resistance in non small cell lung cancer and subcutaneous bleeding: case report
Erschienen in: Reactions Weekly | Ausgabe 1/2017
Einloggen, um Zugang zu erhaltenExcerpt
Author Information-
* death
-
* life-threatening
-
* hospitalisation
-
* disability
-
* congenital anomaly
-
* requires intervention to prevent permanent impairment or damage
-
* Drug interaction